Trial Profile
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Magrolimab (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Forty Seven; Gilead Sciences
- 22 Apr 2020 Status changed from recruiting to completed.
- 25 Jan 2020 Results (n=78) presented at the 2020 Gastrointestinal Cancers Symposium.
- 28 Mar 2019 According to a Forty Seven Inc. media release, the company announced that the updated data from the study is expected in the fourth quarter of 2019.